All In Biotech

Drug Trial Radar · NCT00348504

Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.

Last checked: Nov 19, 2026Latest source record: Nov 20, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,300

Actual

Start

Mar 2003

Primary completion

Not stated

Study completion Jun 2005

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
Collaborators
Orion Corporation, Orion Pharma
First posted
Jul 4, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to compare the efficacy of levosimendan and dobutamine on all-cause mortality in the 180 days following randomization.

Conditions

  • Acute Heart Failure

Interventions

  • levosimendanDrug

  • dobutamineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortality in the 180 days following randomization.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Global Medical Information - Abbott

    Abbott Park, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.